HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate.  With this study, the Hydra will obtain the CE mark and go after FDA approval (just as all new devices). 

HYDRA CE | Surgen nuevos modelos con los que avanza el TAVI

This study looked at safety and performance of the new Hydra valve to treat severe aortic stenosis in high or extreme surgical risk patients. 

Hydra presents a repositionable self-expanding system with supra-annular bovine pericardial leaflets. This emulates the big majority of self-expanding models currently available, as well as those to come.  

The study included 157 patients (79.2 ± 7.1 mean age and 4.7 ± 3.4% STS) with 94.3% successful implantation.

At 30 días, mortality was 7%, including 5.7% cardiovascular deaths; 3.2% were device related.

There was significant improvement of effective orifice area (from 0.7 ± 0.2 cm2 to 1.9 ± 0.6 cm2) and mean aortic valve gradient (from 49.5 ± 18.5 mm Hg to 8.1 ± 3.7 mm Hg). These figures were maintained for a year. 


Read also: Is the Booster Dose Against COVID-19 Effective for All Ages?


Moderate to severe paravalvular leak was observed in 6.3% of patients at 30 days and in 6.9% 1 year. This differs from the observed trend of the rest of self-expanding valves, which tend to show leak improvement at one year. 

Pacemaker implantation rate was 11.7% at 30 days and 12.4% at one year.

Conclusion

This study aiming at obtaining the CE mark, has shown favorable efficacy for the new Hydra, with excellent hemodynamic results and acceptable complications rate. 

Original Title: 30-Day and 1-Year Outcomes With HYDRA Self-Expanding Transcatheter Aortic Valve: The Hydra CE Study.

Reference: Audrius Aidietis et al. JACC Cardiovasc Interv. 2022 Jan 10;15(1):93-104. doi: 10.1016/j.jcin.2021.09.004.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...